- Home
- ENGN vs MRVI Comparison
ENGN vs MRVI Comparison
Compare ENGN & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- MRVI
- Stock Information
- Founded
- ENGN 1999
- MRVI 2014
- Country
- ENGN Canada
- MRVI United States
- Employees
- ENGN N/A
- MRVI N/A
- Industry
- ENGN
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- MRVI Health Care
- Exchange
- ENGN Nasdaq
- MRVI Nasdaq
- Market Cap
- ENGN 379.3M
- MRVI 376.2M
- IPO Year
- ENGN N/A
- MRVI 2020
- Fundamental
- Price
- ENGN $8.54
- MRVI $3.36
- Analyst Decision
- ENGN Buy
- MRVI Hold
- Analyst Count
- ENGN 7
- MRVI 9
- Target Price
- ENGN $20.29
- MRVI $4.54
- AVG Volume (30 Days)
- ENGN 361.4K
- MRVI 1.7M
- Earning Date
- ENGN 09-11-2025
- MRVI 11-06-2025
- Dividend Yield
- ENGN N/A
- MRVI N/A
- EPS Growth
- ENGN N/A
- MRVI N/A
- EPS
- ENGN N/A
- MRVI N/A
- Revenue
- ENGN N/A
- MRVI $219,830,000.00
- Revenue This Year
- ENGN N/A
- MRVI N/A
- Revenue Next Year
- ENGN N/A
- MRVI $7.27
- P/E Ratio
- ENGN N/A
- MRVI N/A
- Revenue Growth
- ENGN N/A
- MRVI N/A
- 52 Week Low
- ENGN $2.65
- MRVI $1.67
- 52 Week High
- ENGN $10.35
- MRVI $8.54
- Technical
- Relative Strength Index (RSI)
- ENGN 60.29
- MRVI 58.21
- Support Level
- ENGN $8.49
- MRVI $3.21
- Resistance Level
- ENGN $8.85
- MRVI $3.65
- Average True Range (ATR)
- ENGN 0.85
- MRVI 0.22
- MACD
- ENGN 0.02
- MRVI 0.01
- Stochastic Oscillator
- ENGN 63.96
- MRVI 58.34
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.